TY - JOUR
T1 - HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population
T2 - The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study
AU - Barr, E. L.M.
AU - Cameron, A. J.
AU - Balkau, B.
AU - Zimmet, P. Z.
AU - Welborn, T. A.
AU - Tonkin, A. M.
AU - Shaw, J. E.
N1 - Funding Information:
Acknowledgements E. L. M. Barr is supported by a National Health and Medical Research Council (NHMRC; 379305)/National Heart Foundation Australia (PP 05M 2346) joint postgraduate scholarship. A. J. Cameron is supported by Postgraduate Research Scholarship (PP 04M 1794) from the National Heart Foundation of Australia. The AusDiab study, co-coordinated by the Baker Heart and Diabetes Research Institute, gratefully acknowledges the generous support given by: National Health and Medical Research Council (NHMRC grant 233200), National Heart Foundation Australia (Research Grant-in-Aid RES17-01 2005) for the collection of and adjudication of medical records and in-kind support from the Australian Institute of Health and Welfare, who provided the mortality data. In addition, we are most grateful to the following for their support: The Commonwealth Department of Health and Aged Care, Abbott Australasia, Alphapharm, AstraZeneca, Aventis Pharmaceutical, Bristol–Myers Squibb Pharmaceuticals, Eli Lilly (Australia), GlaxoSmithKline, Janssen–Cilag (Australia), Merck Lipha, Merck Sharp & Dohme (Australia), Novartis Pharmaceutical (Australia), Novo Nordisk Pharmaceutical, Pharmacia and Upjohn, Pfizer, Roche Diagnostics, Sanofi Synthelabo (Australia), Servier Laboratories (Australia), Bio-Rad Laboratories, HITECH Pathology, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services and Victorian Department of Human Services, and Health Department of Western Australia. For their invaluable contribution to the set-up and field activities of AusDiab, we are enormously grateful to: A. Allman, B. Atkins, S. Bennett, A. Bonney, S. Chadban, M. de Courten, M. Dalton, D. Dunstan, T. Dwyer, H. Jahangir, D. Jolley, D. McCarty, A. Meehan, N. Meinig, S. Murray, K. O’Dea, K. Polkinghorne, P. Phillips, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Whalen and F. Wilson. A special acknowledgement also goes to S. Murray, G. Filby and medical records staff, who helped in the collection of medical record information. Finally, we thank the AusDiab participants for volunteering their time to participate in the study.
PY - 2010/1
Y1 - 2010/1
N2 - Aims/hypothesis: We assessed whether the relationships between insulin sensitivity and all-cause mortality as well as fatal or non-fatal cardiovascular disease (CVD) events are independent of elevated blood glucose, high blood pressure, dyslipidaemia and body composition in individuals without diagnosed diabetes. Methods: Between 1999 and 2000, baseline fasting insulin, glucose and lipids, 2 h plasma glucose, HbA1c, anthropometrics, blood pressure, medication use, smoking and history of CVD were collected from 8,533 adults aged >35 years from the population-based Australian Diabetes, Obesity and Lifestyle study. Insulin sensitivity was estimated by HOMA of insulin sensitivity (HOMA-%S). Deaths and fatal or non-fatal CVD events were ascertained through linkage to the National Death Index and medical records adjudication. Results: After a median of 5.0 years there were 277 deaths and 225 CVD events. HOMA-%S was not associated with all-cause mortality. Compared with the most insulin-sensitive quintile, the combined fatal or non-fatal CVD HR (95% CI) for quintiles of decreasing HOMA-%S were 1.1 (0.6-1.9), 1.4 (0.9-2.3), 1.6 (1.0-2.5) and 2.0 (1.3-3.1), adjusting for age and sex. Smoking, CVD history, hypertension, lipid-lowering medication, total cholesterol and waist-to-hip ratio moderately attenuated this relationship. However, the association was rendered non-significant by adding HDL. Fasting plasma glucose, but not HOMA-%S significantly improved the prediction of CVD, beyond that seen with other risk factors. Conclusions/interpretation: In this cohort, HOMA-%S showed no association with all-cause mortality and only a modest association with CVD events, largely explained by its association with HDL. Fasting plasma glucose was a better predictor of CVD than HOMA-%S.
AB - Aims/hypothesis: We assessed whether the relationships between insulin sensitivity and all-cause mortality as well as fatal or non-fatal cardiovascular disease (CVD) events are independent of elevated blood glucose, high blood pressure, dyslipidaemia and body composition in individuals without diagnosed diabetes. Methods: Between 1999 and 2000, baseline fasting insulin, glucose and lipids, 2 h plasma glucose, HbA1c, anthropometrics, blood pressure, medication use, smoking and history of CVD were collected from 8,533 adults aged >35 years from the population-based Australian Diabetes, Obesity and Lifestyle study. Insulin sensitivity was estimated by HOMA of insulin sensitivity (HOMA-%S). Deaths and fatal or non-fatal CVD events were ascertained through linkage to the National Death Index and medical records adjudication. Results: After a median of 5.0 years there were 277 deaths and 225 CVD events. HOMA-%S was not associated with all-cause mortality. Compared with the most insulin-sensitive quintile, the combined fatal or non-fatal CVD HR (95% CI) for quintiles of decreasing HOMA-%S were 1.1 (0.6-1.9), 1.4 (0.9-2.3), 1.6 (1.0-2.5) and 2.0 (1.3-3.1), adjusting for age and sex. Smoking, CVD history, hypertension, lipid-lowering medication, total cholesterol and waist-to-hip ratio moderately attenuated this relationship. However, the association was rendered non-significant by adding HDL. Fasting plasma glucose, but not HOMA-%S significantly improved the prediction of CVD, beyond that seen with other risk factors. Conclusions/interpretation: In this cohort, HOMA-%S showed no association with all-cause mortality and only a modest association with CVD events, largely explained by its association with HDL. Fasting plasma glucose was a better predictor of CVD than HOMA-%S.
KW - Cardiovascular diseases
KW - Hyperglycaemia
KW - Insulin sensitivity and resistance
KW - Metabolic syndrome
KW - Mortality
UR - https://www.scopus.com/pages/publications/72449205432
U2 - 10.1007/s00125-009-1588-0
DO - 10.1007/s00125-009-1588-0
M3 - Article
C2 - 19894029
AN - SCOPUS:72449205432
SN - 0012-186X
VL - 53
SP - 79
EP - 88
JO - Diabetologia
JF - Diabetologia
IS - 1
ER -